VOOPOO
VOOPOO, a leading vape manufacturer, recently released a review on its development, revealing the underlying driving force of its success against the market backdrop of complicated international relationships, rising operation cost, intensifying competition, and product similarity – the four major innovation models, namely technological innovation to provide long-term momentum, system innovation to ensure lasting vitality, operating innovation to expand company footprint, and product innovation to increase market share.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220310006062/en/
Innovation Model 1 - Technological innovation to provide long-term momentum
Technological innovation, as the foundation, provides a steady impetus for development. VOOPOO has established the strategic concept of investing in technological innovation and developing leading and original technologies.
In 2017, VOOPOO creatively developed the GENE series chips, and collaborated with DRAG to set the world record for fastest ignition speed at that time. Products were loved by more than 4 million users around the world, and are still regarded as an industry icon. In 2019, the innovative size-compatible VINCI became a new trend in Mod Pod. In 2020, DRAG X/S became one of the best-sellers in the world with its super performance and innovative metal-leather design. In 2021, VOOPOO innovatively explored the PNP/TPP/ITO vape platforms, starting to set the new technical standards in the industry.
It is with in-depth research and systematic control of market segments, keen focus on products and technologies, the pioneering and innovative spirit, and the belief in technological innovation, that VOOPOO has proceeded forward in the global market and won the trust of global users.
Since scientific and technological innovation is the primary productive force of an enterprise and the only way to achieve a global leading position, VOOPOO has set up the global innovation center with more than 500 R&D technicians working on projects at the same time. VOOPOO’s innovation model will bring the company more technological breakthroughs and promote the implementation and development of its global strategy.
Innovation Model 2 – System innovation to ensure lasting vitality
System innovation, as the soul, builds an open innovation platform, forms a sound structure from the entire group to each business department, and creates a high-value model for enterprise development. VOOPOO implements a four-level R&D system from research to product development: an innovative platform model integrating research institute, PhD researchers, expert consultants, and innovation projects covering multiple fields such as basic research, new materials, innovative atomization, HNB technology, intelligent manufacturing and modern logistics.
As of 2022, VOOPOO has applied for more than 1,000 cases of intellectual property, and has 3 R&D centers around the world covering basic research, vaping innovation, chip technology, and life science. In addition, VOOPOO has built 6 manufacturing and processing centers which are in line with Good Manufacturing Practice (GMP), covering a total area of 120,000 square meters. At the same time, VOOPOO also cooperates with many universities on innovative materials to build a forward-looking R&D system integrating production, academy and research.
In order to protect independent intellectual property rights and also stimulate creativity, VOOPOO has established a global, full-service, full-process intellectual property management system. In view of the increasing number of competitors and competitive products as well as the rampant counterfeiting, VOOPOO has applied for nearly 600 trademarks around the world, and registered defensive trademarks at the same time to prevent preemptive registration of the same or similar trademarks by third parties, so as to avoid “free riders”, thereby defending the company’s brand and reputation.
In March 2022, VOOPOO’s core trademark was included in the “2021 Guangdong Provincial Key Trademark Protection List”. It is worth noting that among the 580 trademarks on the list, only 3 are from the vaping industry.
In addition, in order to promote compliance and standardization in the global market, VOOPOO implemented the compliance strategy and set up the global compliance department early in 2019. VOOPOO was also deeply engaged in the compilation of China’s GB standard, and has submitted the American PMTA (VOOPOO is among the first batch of PMTA applicants) and involved in the European TPD3 standards.
Innovation Model 3 – Operating innovation to expand company footprint
Operating innovation, as the effective means, enables the company to be open-minded, share resources, build industrial chains, and achieve further growth.
In the Era 1.0 of operation, the upstream is about production, the midstream is about marketing, and the downstream is about channels. They are clearly distinctive to each other and each part can profit greatly. In the Era 2.0, upstream, midstream and downstream obviously become inseparable. Production, marketing and channels are closely intertwined. The ecology of the full industry chain reflects the current strategic demand of terminal consumption, channel distribution and transboundary cooperation.
Based on industry needs, VOOPOO has built the diversified strategic business structure to fully serve the needs of all parties. The company has formed a full industrial chain of vape integrating R&D, production, branding and channels, and has achieved differentiated, unique and irreproducible advantages through the integration of the industrial value chain.
At present, VOOPOO has established absolute market competitiveness on a global scale with more than 200 reserve products every year for different markets in the world. Within 3 years, it has established long-term cooperation relationships with partners in more than 70 countries and regions, and opened 6 overseas branches focusing on localized operations in the United States, UK, Indonesia, Canada and other countries. It has set up a network of 100,000 outlets around the world to shape its global brand influence.
Innovation Model 4 – Product innovation to increase market share
The VOOPOO-style innovation is ultimately product innovation, which further brings VOOPOO a more solid market position.
In the previous 2021 Ecigclick Vape Awards, VOOPOO won the Best Vape Kit For Beginners, the Best POD, the Best MOD, and the Best Sub Ohm Tank respectively with its four products ARGUS, DRAG Nano 2, DRAG 3, TPP-X. The awards reflected VOOPOO’s user-oriented consumer insights and diversified product innovation.
With the evolution of the market environment and technological innovation, users’ demands for vaping products are also constantly upgrading, and scenario-based, lightweight and multi-functional products are increasingly favored by the market. In view of this and driven by user value, VOOPOO decided to enter a new era by launching a portfolio comprising four core product series, DRAG, VINCI, ARGUS, and V, to provide users with more accurate product solutions and to continue to upgrade user experience and explore the global market.
Adhering to the four models, VOOPOO-style innovation has set a good example for the development of vaping companies.
In today’s fast-changing world, long-term thinking for the future is becoming more and more important. VOOPOO will continue to pursue the value guided by the long-term thinking. Confronted with the obstacles commonly shared by the industry, VOOPOO is taking a unique path of innovation development.
“Long-term investment in technological innovation should be planned in a long-term manner. We must dare to embrace uncertainty and strengthen cooperation with partners to truly realize the integration from technology to products,” noted EVEREST, Founder and CEO of VOOPOO.
VOOPOO firmly believes that good products are the foundation of the sustainable development of the industry. The company should be a friend of time and a pioneer of technology, and work with users and partners to jointly drive the sustainable development of the industry. The future will definitely belong to long-termism, and VOOPOO look forward to engaging more partners in its development.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220310006062/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
